TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Composite Achievement of MMP Severity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of apneic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of visits to healthcare professionals related to apneic events
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Area under the percent radiolabeled particle retention-time curve up to 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-53038
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of post-spinal hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Usability of investigational component of PAP system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of investigational component of PAP system (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Liebowitz Social Anxiety Scale (LSAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum observed plasma concentration (Cmax) of a single dose aldafermin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of a single dose aldafermin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum concentration (Tmax) of a single dose aldafermin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of hormonal therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Child's emotional and behavioural symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bleeding on pocket probing (BOPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pocket probing depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of bronchiectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of successful exclusion of the left atrial appendage (LAA) from the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Screening attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in head and trunk position from centerline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the Pediatric Quality of Life Inventory Infant Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to return to full participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toronto Alexithymia Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Spherical Equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Balance as Measured by Timed Up and Go (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-healing wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality of Recovery 15 score (QoR-15)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in hemoglobin concentrations (Hb) during rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in hemoglobin concentrations (Hb) while performing cognitive tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Participant's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability and Usability of Cognitive Remediation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sessions and overall program attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum concentration (Cmax) of midazolam administered alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of metformin administered alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of bupropion administered alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in motor unit firing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in central activation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area under concentration curve from time 0 to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first event of CV death, HF event, LVAD implantation/cardiac transplantation, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of sampling capsule endoscopy system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quantity/Frequency/Peak Alcohol Use Index (QFP) peak item
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microvascular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall hyperpigmentation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Time Where Blood Glucose is between 70-140 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in agitation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with CPAP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 1 Repetition Maximum (1-RM) Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Remission of Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of SOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to be mobilised safely within 6 hours of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Heart Failure Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Heart Failure Caregiving Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in guideline-directed medical therapy by classes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in guideline-directed medical therapy by dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients achieving neutral fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with online learning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The decision preparation scale
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Days of dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pharmacokinetics (PK) Evaluation of INM004
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited local signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited systemic signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant change from baseline for safety laboratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-spending to execute Yale Swallow Protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recovery Time of acute poisoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of ctDNA positive patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Clinically significant Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cancer screening success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in quality of life assessed by (WHOQOL)-BREF Taiwan version
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in quality of life assessed by EORTC QLQ-CR30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in FACT-G version 4
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in FACT-F version 4 at each post-treatment visit compared to baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IgG humoral response to vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: muscle thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: echogenicity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: fasciculations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in DNL in VLDL-triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pelvic floor function (constipation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pelvic floor function (urinary incontinence score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Distinguishing between TB and non-TB coughs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SARS-CoV-2-spike protein-specific binding IgG antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of other diseases associated with smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective markers of Inflammatory Bowel Disease (IBD) Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of Valvular Heart Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Japanese Orthopaedic Association Scores (JOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of Low-Frequency Fluctuation (ALFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional Connectivity (FC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Magnetic Resonance Spectrum (MRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Domestic violence
Endpoint domain: Adverse events/effects
Primary endpoint: Child maltreatment
Endpoint domain: Adverse events/effects
Primary endpoint: Injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Scheduled Treatment Fractions Delivered Successfully
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Simulator sickness questionnaire
Endpoint domain: Adverse events/effects
Primary endpoint: AUCt of JLP-2004
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of JLP-2004
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTc values comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: De novo HBV infected rate after liver transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Grading of cough reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cesarean Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of dysmenorrhea measured by Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who report scores ≥4 for their final rating of the intervention's feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who report scores ≥4 for their final rating of the intervention's acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who report scores ≥4 for their final rating of the intervention's appropriateness for improving psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PCR-confirmed influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serious adverse device effect (SADE)-free rate at 3 months
Endpoint domain: Adverse events/effects
Primary endpoint: Implant Success rate of the Solia S lead in LBB area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Freedom from Device-Related Safety Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Success of the intervention at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average lowest daily Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of Hospitalizations Per Patient Year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants Classified According to Karnofsky Performance Status (KPS) Stratified by IMDC Risk Category
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life/Wellness
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Receiver operating characteristic per lesion and breast level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax after administration of either capsule or tablet formulation in fasted state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability including treatment-emergent AE and treatment-emergent SAE
Endpoint domain: Adverse events/effects
Primary endpoint: type 2-4 bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline BCIS Beck Cognitive Insight Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Beads Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline CBQ Cognitive Bias Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Stress Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Molecular measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported social anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic status of SAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical severity of SAD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pulmonary Artery Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Fluency and Stuttering Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMS-induced (Motor) Evoked Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cervical visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease-of-use
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of patients with synovial sarcoma
Endpoint domain: Mortality/survival
Primary endpoint: Area Under The Concentration-time Curve From Time of Dosing Extrapolated to Time Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Concentration-time Curve From The Time of Dosing to The Last Measurable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QIDS-SR-16 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence rate of serious DMEK post-op complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital Visits and Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of occult left heart disease during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Therapeutic response of chronic pulmonary vasodilator therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Timeliness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the Beck Anxiety Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms (State-Trait Anxiety Inventory)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptoms (Generalized Anxiety Disorder - 7 Item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptoms (Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in symptoms (Depression Anxiety Scale - 42 Item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Hemaglobin A1c (HbA1c) at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in microbiome colonic mucosa: taxa abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbiome colonic mucosa: microbiome diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function of the subject
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Negative and positive symptoms of the subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum nicotine metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Difference in the Signal-to-Noise Ratio 50 (SNR-50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference in Localization Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf, etavopivat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax, etavopivat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events (AEs) defined as DLT
Endpoint domain: Adverse events/effects
Primary endpoint: α-synuclein-related biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and severity of toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Events or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Brain Care Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound Measured Femoral Blood Flow during Passive Limb Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ultrasound Measured Femoral Blood Flow during Active Limb Contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Social Anxiety Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attention Comparison Score (ACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systolic BP (daytime and nocturnal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plaque Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Greyscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes